Robert W. Baird Issues Pessimistic Forecast for MiNK Therapeutics (NASDAQ:INKT) Stock Price

MiNK Therapeutics (NASDAQ:INKT) had its price objective lowered by Robert W. Baird from $8.00 to $4.00 in a research note published on Friday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of MiNK Therapeutics in a research report on Wednesday, October 9th.

MiNK Therapeutics Price Performance

Shares of NASDAQ INKT remained flat at $0.75 during trading on Friday. 33,007 shares of the stock traded hands, compared to its average volume of 89,830. The company has a market cap of $29.81 million, a price-to-earnings ratio of -1.93 and a beta of 0.05. The stock has a 50-day moving average of $0.73 and a 200-day moving average of $0.85. MiNK Therapeutics has a one year low of $0.57 and a one year high of $1.90.

MiNK Therapeutics (NASDAQ:INKT) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.03. On average, research analysts predict that MiNK Therapeutics will post -0.33 EPS for the current fiscal year.

Institutional Investors Weigh In On MiNK Therapeutics

An institutional investor recently raised its position in MiNK Therapeutics stock. Renaissance Technologies LLC raised its holdings in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 127,841 shares of the company’s stock after purchasing an additional 22,613 shares during the quarter. Renaissance Technologies LLC owned 0.37% of MiNK Therapeutics worth $121,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 2.87% of the company’s stock.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.